Adenosine Therapeutics, LLC
United States of America
Dr. Skinner is the representative on the board of Novartis Bioventures, Ltd. Prior to the Novartis Venture Funds he worked as Executive Director and Global Head Strategic Alliances, Therapeutics and Head Strategic Alliances, Technologies at the Novartis Institutes for Biomedical Research where he led a team responsible for identification, negotiation and management of collaborations and licenses for Novartis? therapeutic areas as well as the technology areas. Prior to joining Novartis he was CEO of SelectX Pharmaceuticals and President and CEO of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was also Director of Technology Acquisitions for Pharmacia & Upjohn and Pharmacia managing business development and licensing for Pharmacia?s research platforms and therapeutic areas worldwide, and Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics and earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois. Henry serves on the board of AMP Therapeutics, Galera Therapeutics and works with Cylene, Merus and Forma.
Pharmaceuticals, Medicine , Human and Molecular Genetics , Microbiology , Biochemistry